Theriva Biologics

Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a GAAP net loss of -$3.2M compared to the -$2.66M expected. GAAP EPS of -$0.07 missed the -$0.06 consensus mean. While revenue remained at zero as expected for this clinical-stage biotech, total operating expenses of $3.3M were higher than the projected EBIT loss of $2.5M. The cash position of $11.3M provides a runway into Q1 2027, focusing on the newly initiated VIRAGE2 Phase 2a trial for VCN-01 in pancreatic cancer.